Regression of Lipodystrophy in HIV Patients on Therapy with New Protease Inhibitor Atazanavir

Antiretroviral therapy against HIV has resulted in various metabolic alterations and body fat redistributions. The lipodystrophy syndrome is most often seen in HIV-infected patients treated with protease inhibitors (PI).

Atazanavir (Reyataz) is a novel and potent PI without relevant lipid elevations. In this study, German researchers report on three patients with rapid regression of dorsocervical and abdominal fat accumulations, respectively, after switching antiretroviral therapy from established PI- to atazanavir-based HAART.

HAART has dramatically reduced the morbidity and mortality of HIV-infected patients. However, several metabolic side effects have been described to be associated with long-term HAART. These include hypertriglyceridemia, hypercholesterinemia, insulin resistance, impaired glucose tolerance, and lactic acidemia.

In addition, heterogenous clinical features of body fat changes can be observed frequently in patients receiving HAART. Some patients demonstrate lipoatrophic features, such as the loss of subcutaneous adipose tissue from the face (sunken cheeks) and the extremities. Frequently, patients have concomitant deposits of adipose tissue over the dorsocervical spine, called 'buffalo hump', in the intra-abdominal region, and breast enlargement.

These metabolic alterations and body fat changes have been summarized in the so-called lipodystrophy syndrome, reviewed by Carr (AIDS 17. 2003).

Metabolic abnormalties, especially hypertriglyceridemia, hypercholesterinemia and diabetes mellitus, may lead to an increased risk of cardiovascular disease. The lipodystrophy syndrome has been associated mainly with the use of protease inhibitors (PI), but may also occur in the absence of PI. Therapy-associated physiognomic alterations may lead to stigmatization and thus compromised adherence to antiretroviral therapy.

Lipodystrophy is diagnosed based on the presence of lipoatrophy or fat accumulations by physical examination, technical assessments such as dual-energy X-ray absorptiometry and cross-sectional computerized tomography, and patient's report. The exact role of PI in metabolic changes and the induction of fat redistribution remains unclear. Various definitions of the lipodystrophy syndrome exist and different diagnostic tools are used. An objective case definition has recently been published, and may help to standardize the diagnosis and evaluation of lipodystrophy.

Atazanavir is a new potent and safe azapetide PI, with no clinical effect on total cholesterol and fasting triglyceride levels in HAART-naive patients. In HAART-experienced patients significant decreases were observed in total cholesterol, fasting LDL-cholesterol and fasting triglyceride levels.

In the present study, investigators report on three HIV-infected patients, who were switched to atazanavir from established PI- containing antiretroviral regimens as a result of hyperlipidemia, and reported to the physician a reduction of fat accumulations over the dorsocervical spine, or the abdominal region, respectively.

Case Reports

The three patients were treated in an early access programme of atazanavir (Bristol-Myers Squibb, Germany; Protocol AI424-900) in two medical practices and a university hospital outpatient clinic, respectively.

All three patients were included in the early access programme because of elevated cholesterol and triglyceride levels. After switching to atazanavir from other PI, a reduction in fasting cholesterol, LDL-cholesterol and triglyceride levels was documented. Furthermore, atazanavir achieved sustained virological control and maintained CD4 cell counts. In all patients the total bilirubin value increased under therapy with atazanavir but without clinical significance.

All three patients experienced a decrease in their fat deposits, denoted by a reduction in their collar sizes and a newly recognised 'dent' over the dorsocervical spine (patients 1 and 3), or by a reduction in waist size (American size 31 to 29) in patient 2, respectively.

Clinical and objective signs were a regression of the fat deposits, which remained during therapy of 3 months. The body weight in all patients was stable throughout therapy with the new antiretroviral regimen.

Lipodystrophy is a complex and heterogenous syndrome with various metabolic alterations and clinical features in HIV-infected patients treated with antiretroviral combination drug regimens. In these three patients, the regression of either the dorsocervical fat deposit (buffalo hump) or abdominal obesity was reported after switching antiretroviral therapy from another PI- containing regimen to a therapy containing atazanavir 400 mg once a day.

Clinical changes of the buffalo hump, with a reduction and a central dent over the spine and a reduced waist size, respectively, were obvious. The possibility that these changes could also be influenced by a modification of their daily activities or their diet cannot be excluded. Nonetheless, in all three patients the body weight did not decrease, suggesting that diet or modified physical activities had not had a major influence on these body changes.

In concordance with earlier observations in our three patients, fasting triglyceride and cholesterol levels decreased during therapy with atazanavir. Most notably, switching antiretroviral therapy from established PI to atazanavir led to a regression of pre-existing fat accumulations.

In all three patients atazanavir was given 'unboostered', i.e. without a concomitant dose of 100 mg ritonavir. Interim results at week 16 from one study have shown a superior lipid profile for atazanavir 300 mg/ritonavir 100 mg a day or atazanavir 400 mg/saquinavir 1200 mg a day, respectively, compared with the lopinavir/ritonavir regimen. Whether ritonavir 100 mg has an effect on body fat accumulation is unclear.

Objective assessments of the changes in fat distributions in patients receiving atazanavir are ongoing in two studies. Preliminary analysis of one study revealed only small increases of total body fat and appendicular fat, indicating little evidence of lipdodystrophy for both atazanavir-containing and efavirenz-containing regimens.

In summary, switching to atazanavir 400 mg once a day from other PI-containing antiretroviral regimens resulted in decreases in total cholesterol and fasting triglyceride levels and in a regression of body fat accumulations, whereas the CD4 cell count and viral response were preserved.

The authors conclude, “We propose that in patients with lipodystrophy syndrome, switching to atazanavir from established PI could lead to a reversal of the metabolic alterations and most notably to a rapid regression of pre-existing body fat accumulations.”

04/14/04

Primary Reference

G Haerter and others. Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir. AIDS 18(6): 952-955. April 9, 2004.

Additional References

Behrens GM, Meyer-Olson D, Stoll M, Schmidt RE. Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS 2003; 17:S149-S15S154.

Bristol-Myers Squibb Company. BMS-232632: Atazanavir briefing document, May 2003 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3950B1_01_Bristol MyersSquibb-Atazanavir.pdf. Accessed 15 May 2003.

Bristol-Myers Squibb. Data show HIV patients switched to Bristol-Myers Squibb investigational protease inhibitor may have significant reductions in cholesterol and triglyceride levels (media release). Wallingford, CT, USA: Bristol-Myers Squibb; 11 July 2002.

Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17:S141-S148.

Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 9359:726-735.

Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.

Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio MA, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179-1193.

Goldsmith DR, Perry CM. Atazanavir. Drugs 2003; 16: 1679-1693.

Haas DW, Zala C, Schrader S, Piliero P, Jaeger H, Nunes D, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 2003; 17:1339-1349.

Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 1999; 13:735-737.

Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13:1659-1667.

Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquired Immune Defic Syndr 2003; 1:18-29.